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Summary
Objective: To examine the therapeutic efﬁcacy of an HMG-CoA reductase inhibitor (statin) in rabbit osteoarthritis (OA) in vitro and in vivo.
Methods: In the presence or absence of mevastatin, rabbit chondrocytes and synoviocytes were incubated with Interleukin-1b (IL-1b), and
analyzed by biochemical methods. Thirty-two mature rabbits that underwent bilateral anterior cruciate ligament transaction (ACLT) received
six consecutive weekly intra-articular injections of mevastatin at three different concentrations or a control solution. All animals were sacriﬁced
6 weeks after ACLT, and the knee joints were assessed by morphological, histological, immunohistochemical, and biochemical methods.
Results: Mevastatin inhibited IL-1b stimulation of gene expression of monocyte chemoattractant protein-1 (MCP-1) and matrix-metalloprotei-
nases 3 (MMP-3), in synoviocytes but not chondrocytes. The levels of MCP-1 and MMP-3 productions in synoviocytes were signiﬁcantly
reduced by statin-treatment. In rabbit with OA, intra-articular injection of mevastatin signiﬁcantly reduced cartilage degradation, as assessed
by morphological and histological examinations. Synovial tissues of knees treated with mevastatin showed less severe inﬂammatory
responses with reduced thickness of synovial cell lining and less inﬁltration of subsynovial CD68þmonocyte lineage cells compared to
untreated control knees. Relative mRNA expressions of MCP-1, IL-1b, MMP-3, and MMP-13 were reduced in synovial tissues, but not articular
cartilage, of knees treated with mevastatin compared with untreated control knees.
Conclusion: During the development of experimental OA, intra-articular administration of HMG-CoA reductase inhibitor (statin) reduces
inﬂammatory cell inﬁltration and matrix-degrading enzyme expression, thus limiting cartilage degradation.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA), the most prevalent joint disease, is
characterized by the progressive loss of articular cartilage
that leads to chronic pain and functional restrictions in
affected joints. Currently, there are no pharmacological
treatments that prevent the development of OA1e3. Different
factors can be involved in the development of OA. There is
increasing evidence that synovial inﬂammation plays an
important role in initiating or amplifying cartilage degrada-
tion in OA4e12. In fact, structural changes observed in OA
include a variable degree of synovial inﬂammation as well
as cartilage degradation4. Histologically, OA synovial tissue
shows hyperplasia with an increased number of lining cells
and a mixed inﬂammatory inﬁltrate consisting mainly of
monocyte lineage cells7e10. In the progression of OA, cyto-
kines and matrix-degrading enzymes are thought to inﬂu-
ence cartilage destruction13e15. Matrix-metalloproteinases
(MMPs) are signiﬁcantly upregulated by proinﬂammatory
cytokines, such as IL-1b, produced by activated monocyte*Address correspondence and reprint requests to: Dr Shuichi Matsuda,
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235lineage cells and synoviocytes16,17. MMPs can directly
destroy nearly all components of the cartilage matrix, and
they have a major impact on OA cartilage degeneration.
Recent research for OA treatment has focused on ﬁnding
agents aimed at reducing the catabolic factors in OA, thus
slowing or reversing OA progression.
Statins are competitive inhibitors of hydroxymethylglutaryl
(HMG)-CoA reductase and are used worldwide as the most
effective drug to reduce serum cholesterol levels by inhibiting
the cholesterol biosynthesis pathway18,19. HMG-CoA reduc-
tase catalyzes the conversion of HMG-CoA to mevalonate,
a rate-limiting step in cholesterol biosynthesis20. Recently,
statins have been shown to have anti-inﬂammatory effects
that are unrelated to their lipid-lowering abilities21,22. Numer-
ous studies have conﬁrmed that statins have a wide range of
effects on cells and tissues involved in inﬂammation, such as
inhibiting the production of IL-1b from human peripheral
blood mononuclear cells23,24, MMP-1, -3, -9 from rabbit
macrophages25, MMP-3 from IL-1b-stimulated human
chondrocytes26, and monocyte chemoattractant protein-1
(MCP-1) from human peripheral monocytes27. Moreover,
several animal models have been used to demonstrate
that statins are anti-inﬂammatory drugs in vivo, from simple
models of inﬂammation, such as carrageenan-induced foot-
pad edema28, to more complexmodels such as the collagen-
induced arthritis model of RA29. However, no studies have
examined the effects of statin on an OA animal model.
236 Y. Akasaki et al.: Cartilage degradation in rabbit experimental OABased on the above observations, we examined the poten-
tial of an HMG-CoA reductase inhibitor (statin) as a protective
agent against cartilage degradation and synovial inﬂamma-
tion in OA, both in vitro and in vivo. Firstly, the effect of statin
was evaluated in rabbit chondrocytes and synoviocytes stim-
ulated by IL-1b. Then, a rabbit OAmodel was used to evaluate
the in vivo effect of statin. We hypothesized that inhibiting
synovial inﬂammation by intra-articularly injected statin would
reduce cartilage degradation in experimentally induced OA.Materials and methodsANIMAL AND REAGENTForty Japanese white rabbits, weighing 3.0e3.5 kg and with closed epiph-
yses, were used in this study. Thirty-two rabbits underwent bilateral anterior
cruciate ligament transection (ACLT) using medial arthrotomy30,31. Eight
rabbits were used for sham operated controls and for harvesting primary
chondrocytes and synoviocytes. Approval was obtained from the Institutional
Animal Care and Use Committee prior to performing the study.
Mevastatin (Sigma, St. Louis, MO, USA) of 50 mg was converted from
a lactone to sodium salt by heating at 50C for 1 h in 500 ml of ETOH and
500 ml of 0.1 N NaOH. After adding 3 ml of PBS, the pH of the stock solution
of 10 mg/ml was adjusted to 7.0 using 0.1 N HCl32.CELL ISOLATION AND CULTURECartilage and synovium tissues were obtained from the non-operated
knees and minced aseptically. The cartilage and synovium fragments were
then digested by 1 mg/ml of collagenase (Collagenase N-2, Nitta Gelatin,
Japan) in PBS. Collagenase digestion was carried out at 37C for 4 h with
moderate stirring. Cells obtained after digestion were cultured in six well
microplates at a density of 1.0 105 cells/well and overlaid with 2 ml of
Dulbecco’s Modiﬁed Eagle Medium containing 10% fetal bovine serum
(FBS), at 37C in a humidiﬁed atmosphere of 95% air and 5% CO2.RNA EXTRACTION AND REVERSE TRANSCRIPTION
POLYMERASE CHAIN REACTION (RT-PCR)Cells were pre-treated for 18 h in culture medium containing 5% FBS with
or without mevastatin at 1, 10, and 50 mM, the statin-dosage was determined
as previously reported26, and then stimulated with 1 ng/ml of IL-1b for 3 h. A
control sample cultured in the absence of mevastatin and IL-1bwas also eval-
uated. Cells were then harvested and processed for RT-PCR. Total RNA was
extracted using an RNA extraction kit (ISOGEN, Nippon Gene, Japan), ac-
cording to the manufacturer’s instructions. Complementary DNA was synthe-
sized using 500 ng of RNA and random 9 mers, and then the resulting cDNA
was PCR ampliﬁed using a commercially available kit (TaKaRa RNA PCR Kit
AMV Ver.3.0, TAKARA, Japan). The following primer sequences for rabbit
GAPDH, MCP-1, and MMP-3 were used. GAPDH: forward, 50-GCCAA
GAGGGTCATCATCTC-30; reverse, 50-GCCTGCTTCACCACCTTCTT-30;
MCP-1: forward, 50-GTCTCTGCAACGCTTCTGTGCC-30; reverse, 50-AGT
CGTGTGTTCTTGGGTTGTGG-30; MMP-3: forward, 50-GCCAAGAGATG
CTGTTGATG-30; reverse, 50-AGGTCTGTGAAGGCGTTGTA-30. A cycle
proﬁle consisted of 30 s at 94C for denaturation, 30 s at 53e61C for anneal-
ing, and 30 s at 72C for extension. Electrophoresis of 10 ml of the reaction
mixture on a 1.5% agarose gel containing ethidium bromide was performed
to evaluate the ampliﬁcation and size of the generated fragments.ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)Cells were pre-treated for 18 h in culturemedium containing 5%FBSwith or
without mevastatin (1 mM, 10 mM, and 50 mM) and then stimulated with 1 ng/ml
of IL-1b for 18 h. Culture medium was then collected for ELISA. The levels of
MCP-1 andMMP-3 producedby chondrocyte and synoviocyteweremeasured
using ELISA kits for MCP-1 (Quantikine ELISA kit, R&D systems, USA) and for
MMP-3 (Biotrak ELISA system, GE Healthcare, UK), in accordance with man-
ufacturer’s protocol. Data from ﬁve independent experiments were analyzed.CELL VIABILITY ASSAYThe cell viability assay was carried out as previously described33 using
CellTiter-Glo Luminescent Cell Viability Assay kit (Promega, Madison, WI),
in accordance with manufacturer’s protocol. Luminescence was measured
using Microlumat Plus LB 96 V (EG&G, Berthold, Germany). Data from
ﬁve independent experiments were analyzed.EXPERIMENTAL ANIMAL OA MODELThe rabbits received bilateral ACLT were randomly divided into three
groups based on the following mevastatin-treatments: 0.01 mg/ml (n¼ 8),
0.1 mg/ml (n¼ 16), and 0.5 mg/ml (n¼ 8). Mevastatin was diluted with
normal saline to each concentration and intra-articularly injected at 0.2 ml/kg
of body weight into one side of the knee and the contralateral knee was in-
jected with normal saline as an untreated control. Weekly injections started
on the day of operation, and continued for a total of six injections. Postoper-
atively, all animals were maintained in individual cages and were allowed
unlimited activity. All animals were sacriﬁced 6 weeks after the operation
by an intravenous overdose of anesthesia.GROSS MORPHOLOGICAL EXAMINATIONAll three groups were evaluated by gross morphological examinations. Fol-
lowing sacriﬁce, grossmorphological grading was performed in a blind fashion
after applying India ink. The severity of gross morphological changes was
graded as 1 (intact surface), 2 (discoloration, minimal surface ﬁbrillation), 3
(overt surface ﬁbrillation), and 4 (full-thickness erosion or/and osteophytes)34.HISTOLOGICAL EXAMINATIONArticular cartilage and synovial tissues were histologically examined in all
groups. The medial and lateral femoral condyles of both knees were ﬁxed in
10% neutral buffered formalin. After decalciﬁcation, the femoral condyles were
cut along the sagittal plane and embedded in parafﬁn. Four-micron sections
were stained with safranin-O/fast green and graded according to the Mankin
scale35. Theexaminationwasperformedblindly by twoobservers and the scores
wereaveraged tominimizeobserverbias.Synovial tissues from thesuprapatellar
and infrapatellar fat padswere also processed and stained with hematoxylin/eo-
sin. The grading system was modiﬁed from that described by Pelletier6. The se-
verity of syonovitiswasgraded from0 to 8: (1) synovial liningcell hyperplasiawas
graded0e3þ, where0¼ 1e2 layersof cells, 1þ¼ 3e4 layers, 2þ¼ 5e6 layers,
3þ¼7 layers. (2) Subsynovial mononuclear cell inﬁltration was graded from
0e3þ, where 0¼ none, 1þ¼mild, 2þ¼moderate, 3þ¼ severe. (3) Fibrosis
was graded from 0 to 2þ, where 0¼ none, 1þ¼mild, 2þ¼ severe.TdT-MEDIATED dUTP-BIOTIN NICK END LABELING (TUNEL)
STAINING OF ARTICULAR CARTILAGEThe in vivo effect of mevastatin on chondrocyte apoptosis was examined
using TdT-FragEL DNA Fragmentation Detection Kit (Calbiochem, CA,
USA). Before staining, an antigen-retrieval procedure was performed on
articular cartilage sections by heating in the microwave for 5 min in 10 mM
sodium citrate, pH 6.0. The sections were incubated with 3% H2O2 solution
for 5 min, and then with terminal deoxynucleotidyl transferase (TdT) enzyme
for 1.5 h at 37C. Next, peroxidase streptavidin conjugate was applied to the
sections for 30 min and developed with DAB solution. The sections were
counterstained by 0.3% methyl green. Cells containing fragmented nuclear
chromatin, characteristic of apoptosis, exhibited a brown nuclear staining.IMMUNOHISTOCHEMICAL EXAMINATION
OF SYNOVIAL TISSUESWe used the CSA II Biotin-free Tyramide Signal Ampliﬁcation System
(DakoCytomation, Carpinteria, CA, USA) according to the manufacturer’s
instructions. The specimens of synovial tissues were ﬁrst incubated with
peroxidase block for 5 min to quench endogenous peroxidase activity. The
specimens were then incubated for 5 min with a protein block, followed by
a 90-min incubation with a commercially available antibody against CD68
(Serotek, Oxford, UK) or a negative control reagent. This was followed by
sequential 15-min incubations with anti-mouse immunoglobulinseHRP,
ﬂuorescyl-tyramide hydrogen peroxide and anti-ﬂuoresceineHRP. Staining
was completed by a 1-min incubation with 3,30diaminobenzidine tetrahydro-
chloride/hydrogen peroxide. Finally, sections were stained with hematoxylin
for 2 min. Quantitative analysis was performed on all synovial tissue sam-
ples36. A single assessor, who was unaware of the category of OA tissue,
systematically examined all sections throughout their entire area. Olympus
BX51 microscope was used to examine the sections under 400 magniﬁca-
tion. A cell was regarded as exhibiting positive staining if a nucleus was
identiﬁed in association with appropriate staining. Scoring the sections was
achieved by counting the number of positively staining cells per ﬁeld.GENE EXPRESSION ANALYSIS OF CARTILAGE
AND SYNOVIAL TISSUES BY RT-PCRCartilage and synovial tissues from eight rabbits treated with 0.1 mg/ml
of mevastatin were harvested and stored frozen in liquid nitrogen until use.
Fig. 1. Effects ofmevastatin on gene expressions ofMCP-1 andMMP-3 in chondrocytes and synoviocytes.MessengerRNAexpressions ofMCP-1
and MMP-3 in chondrocytes and synoviocytes were stimulated by IL-1b. Incubation with mevastatin at three different concentrations did not affect
gene expression of chondrocytes in the presence of IL-1b (A). However, Incubation with 10 mM and 50 mMmevastatin inhibited IL-1b stimulation of
MMP-3 gene expression in synoviocytes (B). MCP-1 gene expression with 50 mMmevastatin was also not stimulated by IL-1b. Each RT-PCR was
performed in duplicate and yielded almost identical results. The data was a representative result from three independent experiments.
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enized. Messenger RNA were then extracted and processed for RT-
PCR. In addition to MCP-1 and MMP-3, IL-1b, and collagen type 2, and
MMP-13 gene expressions were also analyzed. The primer sequences
were as follow; IL-1b: forward, 50-TGCTGTCCAGACGAGGGCAT-30;
reverse, 50-ACTCTCCAGCTGCAGGGTAG-30; COL2: forward, 50-CCAC
GCTCAAGTCCCTCAA-30; reverse, 50-ACGGTCTTGCCCCACTTAC-30;
MMP-13: forward, 50-GATGCCATTACCAGTCTCC-3; reverse, 50-GCTGTA
TTCAAACTGTATGG-30. Scion Image analysis software (Scion Corpora-
tion, Frederik, MD, USA) was used to semi-quantitatively analyze RT-
PCR proﬁles following agarose gel electrophoresis and ethidium bromide
visualization. The Scion Image measures relative mean density over a ﬁxedFig. 2. Effects of mevastatin on the productions of MCP-1 and MMP-3 in
chondrocytes and synoviocytes were stimulated by IL-1b. Mevastatin at 5
MMP-3 from chondrocytes, although not signiﬁcantly. In contrast, incubat
MCP-1 and MMP-3 progray scale range after correction for background. All values were normal-
ized to GAPDH.STATISTICAL ANALYSISAll data are expressed as the means SD. The gross morphology
data were analyzed using a non-parametric ManneWhitney U test.
ELISA and cell viability assay data were analyzed by unpaired t test.
Histology, immunohistochemistry and gene expression data were ana-
lyzed by a paired t test. P values less than 0.05 were considered
signiﬁcant.chondrocytes and synoviocytes. MCP-1 and MMP-3 productions in
0 mM slightly reduced the IL-1b-induced productions of MCP-1 and
ion with 50 mM mevastatin signiﬁcantly inhibited IL-1b stimulation of
ductions (n¼ 5).
Fig. 3. Effects of mevastatin on cell viability in chondrocytes and synoviocytes. Incubation with mevastatin at three different concentrations for
24 h did not affect cell viability in both chondrocytes and synoviocytes (n¼ 5).
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MCP-1 AND MMP-3 GENE EXPRESSIONS IN
CHONDROCYTES AND SYNOVIOCYTESMessenger RNA expressions of MCP-1 and MMP-3 in
chondrocytes were stimulated by IL-1b [Fig. 1(A)]. Incuba-
tion with mevastatin at three different concentrations did
not affect gene expression of chondrocytes in the presence
of IL-1b. Figure 1(B) showed that IL-1b stimulation of syno-
viocytes was able to increase MCP-1 and MMP-3 gene
expressions. However, incubation with 10 mM and 50 mM
mevastatin inhibited IL-1b stimulation of MMP-3 gene
expression in synoviocytes. MCP-1 gene expression with
50 mM mevastatin was also not stimulated by IL-1b.INHIBITORY EFFECTS OF MEVASTATIN ON IL-1b-INDUCED
MCP-1 AND MMP-3 PRODUCTIONS IN
CHONDROCYTE AND SYNOVIOCYTESIncubation with IL-1b enhanced the productions of MCP-1
and MMP-3 by chondrocytes and synoviocytes in the
absence of mevastatin [Fig. 2]. Mevastatin at 50 mM slightly
reduced the IL-1b-induced excess productions of MCP-1
and MMP-3 from chondrocytes, although not signiﬁcantly.
In contrast, incubation with 50 mM mevastatin signiﬁcantly
inhibited IL-1b stimulation of MCP-1 and MMP-3 produc-
tions without adverse effect on cell viability [Fig. 3].EXPERIMENTAL ANIMAL OA MODELTable I
Morphological assessment of femoral condyles. *P< 0.05
Normal saline Mevastatin
A. 0.01 mg/ml of mevastatin treated group (n¼ 8)
Grade 3.25 (1.03) 3.00 (1.30)
B. 0.1 mg/ml of mevastatin treated group (n¼ 8)
Grade 3.25 (0.70) 2.00 (1.07)*
C. 0.5 mg/ml of mevastatin treated group (n¼ 8)
Grade 3.00 (0.92) 2.00 (0.92)*Gross morphological evaluation of articular cartilage
There was no rabbit which had body weight loss or left-
right asymmetric gait at the time of each injection. All
knee joints exhibited complete transection of the ACL and
varying degrees of OA progression were noted at the time
of evaluation. Condyles in knees treated with 0.1 mg/ml
and 0.5 mg/ml of mevastatin showed signiﬁcantly less
cartilage damage than those in the contralateral control
knees (Table I). However, condyles in knees treated with
0.01 mg/ml of mevastatin showed the same degree of
cartilage damage as those in contralateral control knees.
Histological evaluation of articular cartilage
Histological evaluation of articular cartilage demonstrated
a same trend as morphological evaluation. In the control
knees, severe cartilage degradation was noted, includingcomplete disorganization, moderate to severe hypocellularity
and reductions in Safranin-O staining [Fig. 4(A)]. In contrast,
condyles in knees treated with 0.1 mg/ml and 0.5 mg/ml of
mevastatin showed less histological changes than the control
knees [Fig. 4(B)] (Table II). However, no signiﬁcant differ-
ences in the Mankin score were observed between the
0.01 mg/ml of mevastatin treated and the control knees. In
the lesion of control knees, some chondrocytes displayed
a positive TUNEL reaction [Fig. 4(C)]. Intra-articular injection
of mevastatin did not affect chondrocyte apoptosis [Fig. 4(D)].
Histological and immunohistochemical evaluation
of synovial tissues
Histological examination showed that the severity scores
for synovitis in the knees treated with 0.1 mg/ml and 0.5 mg/
ml of mevastatin were signiﬁcantly lower than in the control
knees, especially the degree of synovial lining cell hyperplasia
and subsynovial mononuclear cell inﬁltration (Table III).
Representative photographs of CD68 immunohistochemical
staining indicate that the subsynovial cell inﬁltrate mainly con-
sisted of CD68 positive monocyte lineage cells [Fig. 5]. The
intensity of CD68 positive cells’ inﬁltration was signiﬁcantly
fewer in the knees treated with 0.1 mg/ml and 0.5 mg/ml
of mevastatin than the control knees. The mean numbers of
CD68 positive cells in the knees treated with 0.01 mg/ml of
mevastatin were similar to those in the control knees.
In vivo effects of mevastatin on gene expression
in cartilage and synovial tissue
Each RT-PCR was performed in triplicate and yielded
almost identical results. Representative results are shown
in Fig. 6. There was no signiﬁcant difference in gene ex-
pression between mevastatin treated and control cartilage
[Fig. 6(A)]. In contrast, messenger RNA levels of MCP-1,
Fig. 4. Histological ﬁndings of articular cartilage in an untreated knee and a mevastatin (0.1 mg/ml)-treated knee. Safranin-O staining (A and B)
and TUNEL staining (C and D) were performed. The center of the cartilage lesion on the femoral condyle in an untreated knee and mevastatin
treated knee are shown in (A and C) and (B and D), respectively. (Original magniﬁcation 200).
239Osteoarthritis and Cartilage Vol. 17, No. 2IL-1b, MMP-3, and MMP-13 were signiﬁcantly decreased in
the mevastatin treated synovial tissue compared to the
control synovial tissue [Fig. 6(B)].Discussion
This study is the ﬁrst to demonstrate the effects of
mevastatin on articular cartilage and synovial tissue inTable II
Histological quantification of articular cartilage. Values are the
means SD. *P< 0.05
Normal saline Mevastatin
A. 0.01 mg/ml of mevastatin treated group (n¼ 8)
Structure 4.37 (2.01) 3.75 (2.22)
Cells 2.43 (1.11) 1.75 (1.25)
Safranin-O staining 3.22 (1.01) 2.62 (1.35)
Total score 10.03 (4.11) 8.12 (4.77)
B. 0.1 mg/ml of mevastatin treated group (n¼ 8)
Structure 4.39 (1.26) 2.51 (1.41)*
Cells 2.09 (1.02) 0.69 (1.04)*
Safranin-O staining 2.80 (1.03) 1.48 (1.17)*
Total score 9.34 (2.97) 4.70 (3.26)*
C. 0.5 mg/ml of mevastatin treated group (n¼ 8)
Structure 3.62 (1.84) 2.14 (1.27)*
Cells 1.75 (1.25) 0.81 (0.75)*
Safranin-O staining 2.31 (1.49) 1.60 (1.01)
Total score 7.68 (4.42) 4.56 (2.90)*experimentally induced OA. We addressed the hypothesis
that inhibiting synovial inﬂammation by intra-articular injec-
tion of mevastatin reduces cartilage degradation in experi-
mentally induced OA. The rationale for the present study
was based on previous reports that synovial inﬂammation
occurs in OA development4e12 and that statins can prevent
inﬂammatory responses by suppressing monocyte chemo-
taxis and reducing the release of proinﬂammatory cytokines
and MMPs in vitro and in vivo21e27.Table III
Histological quantification of synovium tissue. Values are the
means SD. *P< 0.05
Normal saline Mevastatin
A. 0.01 mg/ml of mevastatin treated group (n¼ 8)
Lining cell layer 1.62 (0.51) 1.49 (0.43)
Subsynovial cell inﬁltration 1.87 (0.66) 1.87 (0.88)
Fibrosis 1.37 (0.37) 1.33 (0.43)
Total score 4.99 (1.01) 4.95 (1.32)
B. 0.1 mg/ml of mevastatin treated group (n¼ 8)
Lining cell layer 1.55 (0.48) 0.89 (0.75)*
Subsynovial cell inﬁltration 2.37 (0.45) 1.19 (0.74)*
Fibrosis 1.27 (0.49) 1.12 (0.53)
Total score 5.89 (1.13) 3.55 (1.55)*
C. 0.5 mg/ml of mevastatin treated group (n¼ 8)
Lining cell layer 1.87 (0.66) 1.33 (0.50)*
Subsynovial cell inﬁltration 2.16 (0.64) 1.16 (0.35)*
Fibrosis 1.37 (0.41) 1.29 (0.65)
Total score 5.87 (1.06) 3.91 (1.07)*
Fig. 5. Immunohistochemical ﬁndings in synovial tissue from a control knee (A and C) and a mevastatin (0.1 mg/ml)-treated knee (B and D).
Sections were immunostained with an antibody against CD68. Round shape cells were CD68 positive, whereas ﬁbrous cells were not.
(Original magniﬁcation 100 in A and B; 400 in C and D). E: The mean numbers of positively staining cells per ﬁeld (n¼ 8). Values are
the means SD (*P< 0.05).
240 Y. Akasaki et al.: Cartilage degradation in rabbit experimental OAExperimental OA induced by ACLT in rabbits is the most
widely used animal model to examine OA disease-
modifying therapies by intra-articular administration. This
model is characterized by gradual and progressive changes
in the morphology, histology, and gene expression of artic-
ular cartilage and synovial tissues37e39. The primary
mechanism in this model is increased mechanical stress
to articular cartilage. Mechanical stress generates cartilage
fragments, which induce secondary synovial inﬂammatory
responses including migration of monocyte lineage cells
and release of cytokines and matrix-degrading enzymes.
This vicious cycle is considered one of the major causes
of progressive cartilage degradation in OA1,40.Our data demonstrate that intra-articular administration
of mevastatin reduces the extent and severity of cartilage
degradation in experimentally induced OA. Analyses of
synovial tissues showed that synovial lining cell hyperpla-
sia and subsynovial inﬁltration of CD68þmonocyte line-
age cells were signiﬁcantly lower in the statin treated
knees than the control knees. Gene expressions of
MCP-1, IL-1b, MMP-3 and MMP-13, which are major
cytokines and matrix-degrading enzymes in OA, were
decreased in the statin treated synovium but not cartilage
compared with the control. Moreover, the results of in vitro
study showed that mevastatin decreased gene expression
and production of MCP-1 and MMP-3 in synoviocytes
Fig. 6. Comparative mRNA expression in control knees and mevastatin (0.1 mg/ml)-treated knees. There was no signiﬁcant difference in gene
expression between mevastatin treated and control cartilage (A). In contrast, messenger RNA levels of MCP-1, IL-1b, MMP-3, and MMP-13
were signiﬁcantly decreased in the mevastatin treated synovial tissue compared to the control synovial tissue (B) (n¼ 8). Values are the
means SD (*P< 0.05).
241Osteoarthritis and Cartilage Vol. 17, No. 2stimulated by IL-1b. These ﬁndings support our hypothesis
that statins provide OA disease-modifying effects by inhib-
iting synovial inﬂammation and subsequently reducing
cartilage degradation.
The anti-inﬂammatory effects of statins were ﬁrst
demonstrated in coronary artery disease where statin-
treatment inhibited arterial wall inﬂammation and stabilized
atherosclerotic plaques, which reduced cardiovascular
morbidity and mortality41. One of the possible anti-
inﬂammatory mechanisms of statins can be explained by
reduced MCP-1 production27,41, which inhibits circulating
monocytes from migrating to the arterial wall during
atherogenesis. In this study, genetic analysis showed de-
creased MCP-1 expression in both statin treated synovium
and cultured synoviocytes. In addition, the production of
MCP-1 from synoviocytes was signiﬁcantly reduced by
statin-treatment. Decreased MCP-1 expression might be
one reason why the synovial tissues from statin treated
knees had less synovial cell lining hyperplasia and
reduced subsynovial cellular inﬁltration, which mainly
consisted of CD68þmonocyte lineage cells, than control
knees. This reduction of synovial inﬁltration of inﬂamma-
tory cells might contribute to the chondroprotective effect
of statin on experimental OA.
Another possible mechanism for the chondroprotective
effect of statin on experimental OA is direct inhibition of
matrix-degrading enzymes production from synovial
tissues. Statins have been reported to decrease theproduction of MMP-3 from IL-1b-stimulated chondrocytes26
and MMP-1, -3, -9 from macrophages25. In this study, we
examined matrix-degrading enzyme genes that cause
destructive changes in OA cartilage. The gene expression
analysis results showed that MMP-3 and MMP-13 expres-
sion were signiﬁcantly decreased in statin treated synovium
after OA induction. Moreover, the release of MMP-3 from
synoviocytes was signiﬁcantly inhibited by statin-treatment.
The direct downregulation of MMPs by statin might reduce
cartilage degradation in this model.
The distinct results in chondrocytes and synoviocytes
were observed both in vitro and in vivo, which implies
that statin had little impact on gene expressions of cyto-
kines and MMPs in chondrocytes compared to synovio-
cytes. The mechanism of the inhibitory effects of statin
on MMPs’ production in various cell populations is still
controversial. Several recent studies reported that statin
inhibits MMP-9 mRNA expression in different cell lines
such as ﬁbroblast42, osteoblast, ﬁbrosarcorma cells43,
and myoblast44. In contrast, Bellosta et al.45 demonstrated
that statins reduce MMP-9 production by macrophages
without any interference in MMP-9 gene expression.
Luan et al.25 also reported that statins are able to inhibit
the production of MMP-1, -2, -3, and -9 in vascular smooth
muscle cells and macrophages without producing any
change in MMP mRNA levels. In chondrocytes, Lazzerini
et al.26 reported that statin reduces MMP-3 production in
human chondrocytes stimulated by IL-1b and suggested
242 Y. Akasaki et al.: Cartilage degradation in rabbit experimental OAthat the inhibition of isoprenoid synthesis by statin, which
leads to the interference of membrane protein trafﬁc, plays
an important role in reduction of MMP-3 secretion by chon-
drocytes. Our data also showed mevastatin at 50 mM
decreased productions of MCP-1 and MMP-3 in chondro-
cytes, although not signiﬁcantly. It is possible that statin
can inhibit MMPs’ secretion in post-transcriptional mecha-
nism without downregulation of mRNA expression in
some cell populations. However, the mechanism of the
differential effects of statin on chondrocytes and synovio-
cytes still remains to be identiﬁed.
In this study, we selected mevastatin because it is
lipophilic and can passively diffuse into cells at a dose-
dependent rate, like other lipophilic statins such as simvas-
tatin and lovastatin. To determine the optimal mevastatin
concentration, we examined three rabbit groups treated
with different mevastatin concentrations. Twenty-fold of
the in vitro effective concentrations of mevastatin were ap-
plied to the in vivo experiments in consideration of diluting
effect in the joint cavity. The gross morphology, histology,
and immunohistochestry results showed that a concentra-
tion greater than 0.1 mg/ml was necessary for effective
results, whereas a concentration of 0.01 mg/ml did not
show any effective results compared with the saline con-
trol. The result of in vitro study also showed the same
tendency of in vivo study. Mevastatin competitively inhibits
the mevalonate pathway; therefore, concentrations above
a certain level of inhibition would be required to induce
both the in vitro and in vivo effects of statin on OA devel-
opment. Additionally, the effective concentrations used
both in vitro and in vivo were higher than human therapeu-
tic Cmax value of 0.1e1 mM for hypercholesterolemia,
however, any detrimental effect of statin on cell viability
and cell apoptosis was not found.
The method of statin administration is also an important
issue when its anti-inﬂammatory effect is applied to joint
diseases. A recent study of collagen-induced arthritis,
a murine RA model, suggested that intra-peritoneal admin-
istration of simvastatin suppresses the progression of
acute to chronic joint inﬂammation in vivo29. However,
very high statin doses, such as 40 mg/kg/day, by systemic
administration were required for beneﬁcial anti-inﬂamma-
tory effects. In contrast, in this study we showed that
intra-articular injections of mevastatin at 0.02 mg/kg/week
had beneﬁcial effects on articular cartilage and synovial
tissues in a rabbit model. Human clinical therapeutic
dosage for hypercholesterolemia is known as less than
1.5 mg/kg/day. There is, however, the difference of drug
effectiveness among animal species, high serum concen-
trations of statins increase the risk of systemic myositis
with rhabdomyolysis known as the statin-associated side-
effect46. Therefore, our data provide a proof-of-concept
approach of statins as an OA therapy when administered
by intra-articular injection, which is a commonly used tech-
nique in clinical practice.
In conclusion, we demonstrate a novel therapeutic effect
of statin that may be applicable to OA. Intra-articular injec-
tions of statin during OA development could reduce the
inﬁltration of inﬂammatory cells and the expression of
matrix-degrading enzymes, thus limiting cartilage degrada-
tion. The anti-inﬂammatory effects of statin have been
reported in previous in vitro and in vivo studies, whereas,
to our knowledge, this study is the ﬁrst to demonstrate the
chondroprotective effect of statin in an instability-induced
OA model. The results of this study suggest that intra-
articular injection of statin can be promising as a disease-
modifying therapy for human OA.Conﬂict of interest
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